Samsung Biologics posted Q2 2026 operating profit of 586.4 billion won, up 22.9% year-over-year, despite labor strike disruptions to batch production. Revenue reached 1.3209 trillion won, a 30.2% increase from the same period last year, driven by full operation of Plants 1-4, expanded sales contributions from Plant 5 and the Rockville facility in the United States, and favorable foreign exchange rates. The company maintained an operating margin above 40% even as it recognized upfront costs related to the ramp-up of Plant 5 and the Rockville production site ahead of full-scale revenue recognition from those facilities.
Samsung Biologics Reports Q2 2026 Financial Performance
Samsung Biologics disclosed provisional Q2 2026 consolidated results on the 23rd, showing revenue of 1.3209 trillion won and operating profit of 586.4 billion won. Revenue increased 30.2% and operating profit rose 22.9% compared to the same period last year. The company attributed the robust growth to the full-capacity operation of Plants 1 through 4 and favorable foreign exchange conditions. Operating margin remained in the 40% range despite advance recognition of costs associated with Plant 5 and the Rockville production facility prior to full-scale revenue contribution from those sites.
As of the end of Q2 2026, the company's assets totaled 12.6526 trillion won, equity stood at 8.3619 trillion won, and liabilities amounted to 4.2907 trillion won. The debt-to-equity ratio was 51.3%, and the borrowing ratio was 11.5%.
Samsung Biologics Maintains Annual Revenue Growth Guidance
Samsung Biologics expressed confidence in achieving the upper end of its annual revenue growth guidance of +15-20% year-over-year, despite some batch production disruptions caused by a labor union strike. The company continues to pursue contract manufacturing organization (CMO) and contract development organization (CDO) orders across all business areas. Since its founding, Samsung Biologics has accumulated 115 CMO contracts and 176 CDO contracts, with total cumulative orders reaching $21.7 billion.
Samsung Biologics Expands CDMO Business and Production Capacity
Samsung Biologics plans to open a European sales hub in the Netherlands within the third quarter to accelerate its global market penetration. The company decided to acquire Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO), as part of its ongoing business expansion. Beyond its core antibody drug business, Samsung Biologics has secured development and production capabilities for diverse new modalities including messenger RNA (mRNA) and antibody-drug conjugates (ADC). The company also secured land for a Third Biocampus to build high-value new modality production facilities.
FAQ
What were Samsung Biologics' Q2 2026 financial results?
Samsung Biologics reported Q2 2026 revenue of 1.3209 trillion won and operating profit of 586.4 billion won, representing year-over-year increases of 30.2% and 22.9% respectively.
How many cumulative orders has Samsung Biologics secured?
Since its founding, Samsung Biologics has accumulated 115 CMO contracts and 176 CDO contracts, with total cumulative orders reaching $21.7 billion.
